<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907123</url>
  </required_header>
  <id_info>
    <org_study_id>SERENA trial</org_study_id>
    <nct_id>NCT04907123</nct_id>
  </id_info>
  <brief_title>Systematic Escalation of diuREtics With Natriuresis in Heart Failure Patients: SERENA Trial</brief_title>
  <acronym>SERENA</acronym>
  <official_title>Systematic Escalation of diuREtics With Natriuresis in Heart Failure Patients: SERENA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present is a multicenter, prospective, randomized, open-label, blinded end-point trial&#xD;
      aiming to investigate the clinical benefit of a stepwise, natriuresis-driven diuretic&#xD;
      strategy versus standard diuretic treatment in patients with acute decompensated heart&#xD;
      failure with reduced ejection fraction (HFrEF) and low early urinary sodium excretion. The&#xD;
      study will focus on patients at increased risk of resistance to diuretic therapy. In&#xD;
      particular, patients admitted to the emergency department and cardiac intensive care unit due&#xD;
      to an on-chronic or de-novo acute decompensated HF episode with a predominantly &quot;wet&quot; profile&#xD;
      and low early spot urinary sodium (UNa+) excretion will be considered. Spot natriuresis is a&#xD;
      low-cost, non-demanding laboratory test in use to identify diuretic-resistant patients with&#xD;
      an inherent poor prognosis. Whether the early identification of diuretic resistant patients&#xD;
      and the consequent more aggressive treatment may lead to a better outcome has not been&#xD;
      demonstrated by randomized studies. This trial aims to assess if an intensive stepwise&#xD;
      diuretic approach guided by systematic urinary output assessment including natriuresis&#xD;
      evaluation versus a standard diuretic strategy based on urinary output alone effectively&#xD;
      leads to faster euvolemia achievement and better prognosis in a real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of significant reduction of congestion defined as absolute reduction of at least 1 point in wet score grading of congestion after 48 hours of treatment</measure>
    <time_frame>48 hours</time_frame>
    <description>Assessment of WET score (Gheorghiade et al, EJHF 2010)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment failure, defined as persistent congestion (graded by wet score â‰¥12/20) after 24, 48 and 72 hours of diuretic treatment or need for renal replacement therapy.</measure>
    <time_frame>24,48 and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from congestion at 48 hours, defined as jugular venous pressure of &lt;8 cm, with no orthopnea and with trace peripheral edema or no edema</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening or persistent heart failure</measure>
    <time_frame>48 hours</time_frame>
    <description>worsening heart failure symptoms or failure of the patient's condition to improve with treatment requiring the initiation of intravenous inotropic therapy and/or the implementation of mechanical circulatory or ventilatory support up until 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of all-cause mortality, urgent LVAD implant or Heart Transplantation at 30 and 90 days.</measure>
    <time_frame>30 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac cause mortality</measure>
    <time_frame>30 and 90 days</time_frame>
    <description>including myocardial infarction, irreversible heart failure, cardiogenic shock, fatal arrhythmic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for heart failure</measure>
    <time_frame>30 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening renal function</measure>
    <time_frame>48 hours</time_frame>
    <description>absolute increase in serum creatinine &gt; 0.3 mg/dl or &gt; 1,5-fold from baseline at any time from randomization to 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypokalemia, severe hyponatremia or symptomatic electrolytes disorders during treatment protocol</measure>
    <time_frame>72 hours</time_frame>
    <description>hypokalemia &lt;3 mEq/L, severe hyponatremia &lt;125 mEq/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe symptomatic hypotension</measure>
    <time_frame>72 hours</time_frame>
    <description>Systolic arterial pressure &lt; 80 mmHg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to oral switch of diuretic treatments</measure>
    <time_frame>90 days</time_frame>
    <description>days</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to discharge from hospital</measure>
    <time_frame>90 days</time_frame>
    <description>days</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Urinary output and urine output/40 mg furosemide</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>ml/mg furosemide</description>
  </other_outcome>
  <other_outcome>
    <measure>Variation of body weight and body weight/40 mg furosemide</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>kg/mg furosemide</description>
  </other_outcome>
  <other_outcome>
    <measure>Variation of NT-proBNP at 48 hours</measure>
    <time_frame>48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Variation of wet score at 24 and 72 hours</measure>
    <time_frame>24 and 72 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dyspnea severity variation at 24 and 48 hours assessed by dyspnea Visual Assessment Scale (VAS).</measure>
    <time_frame>24 and 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fluid balance</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
    <description>In/out fluid balance</description>
  </other_outcome>
  <other_outcome>
    <measure>Time spent in Intensive Cardiac Intensive Care Unit</measure>
    <time_frame>90 days</time_frame>
    <description>days</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>UNa+ Driven Intensive Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 6 hours; if therapeutic goal is not met, treat according to the following step.&#xD;
Therapeutic goal: Spot Urinary Sodium &gt; 70 mEq/L AND mean diuresis &gt; 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 12 hours; if therapeutic goal is not met, treat according to the following step.&#xD;
Therapeutic goal: mean diuresis &gt; 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive sodiuria-guided diuretic treatment</intervention_name>
    <description>Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment</description>
    <arm_group_label>UNa+ Driven Intensive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard diuretic treatment</intervention_name>
    <description>Stepwise diuretic therapy based on diuresis assessment</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission for acute decompensate chronic heart failure or acute de novo heart failure&#xD;
&#xD;
          -  Ejection Fraction &lt;40%&#xD;
&#xD;
          -  Severe signs and symptoms of congestion with modified wet score â‰¥ 12&#xD;
&#xD;
          -  Spot urinary sodium excretion â‰¤ 70 mEq/L at 2 hours from first intravenous loop&#xD;
             diuretic administration&#xD;
&#xD;
          -  Systolic blood pressure â‰¥90 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reversible etiology of acute heart failure (including acute coronary syndromes,&#xD;
             myocarditis, acute pulmonary embolism, acute rhythm disorders, severe organic valve&#xD;
             disease)&#xD;
&#xD;
          -  Cardiogenic shock at admission or sign of hypoperfusion needing inotropic agents or&#xD;
             mechanical circulatory support.&#xD;
&#xD;
          -  eGFR lower than 15 ml/min/1.73m2 or dialysis&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Frea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O.U. CittÃ  della Salute e della Scienza, Torino, Italia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Frea, MD</last_name>
    <phone>+390116335570</phone>
    <email>frea.simone@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.O.U. CittÃ  della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>To</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Simone Frea, MD</last_name>
      <phone>0116335570</phone>
      <email>frea.simone@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A.O.U. CittÃ  della Salute e della Scienza - Molinette Hospital</investigator_affiliation>
    <investigator_full_name>Simone Frea</investigator_full_name>
    <investigator_title>MD, Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

